Literature DB >> 14638513

Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Ken B Waites1, Donna M Crabb, Lynn B Duffy.   

Abstract

We determined in vitro susceptibilities for ABT-492 and other antimicrobials against Mycoplasma pneumoniae, Mycoplasma fermentans, Mycoplasma hominis, and Ureaplasma species. ABT-492 MICs were < or =1 microg/ml, and the agent was bactericidal against selected isolates of M. pneumoniae and M. hominis. ABT-492 has potential for treatment of infections due to these microorganisms.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14638513      PMCID： PMC296221          DOI： 10.1128/AAC.47.12.3973-3975.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.

Authors:  K Hamamoto; T Shimizu; N Fujimoto; Y Zhang; S Arai
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

Authors:  C M Bébéar; H Renaudin; A Boudjadja; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

3.  Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.

Authors:  C M Bebear; H Renaudin; A Bryskier; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.

Authors:  G E Kenny; T M Hooton; M C Roberts; F D Cartwright; J Hoyt
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

5.  In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.

Authors:  K B Waites; K C Canupp; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

Authors:  George G Zhanel; Lorraine Palatnick; Kimberly A Nichol; Tracy Bellyou; Don E Low; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

Authors:  George G Zhanel; Lorraine Palatnick; Kimberly A Nichol; Don E Low; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191
  10 in total
  17 in total

Review 1.  New Horizons in Mycoplasma genitalium Treatment.

Authors:  Catriona S Bradshaw; Jorgen S Jensen; Ken B Waites
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

2.  Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  C Tagliabue; C Techasaensiri; J P Torres; K Katz; C Meek; T R Kannan; J J Coalson; S Esposito; N Principi; R Leff; J B Baseman; R D Hardy
Journal:  J Antimicrob Chemother       Date:  2011-07-25       Impact factor: 5.790

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.

Authors:  Jennifer Shiu; Grace Ting; Tony Kl Kiang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

Review 4.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Robert K Flamm; Paul R Rhomberg; Michael D Huband; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.

Authors:  S Pereyre; H Renaudin; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 7.  Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.

Authors:  Vanessa R Anderson; Caroline M Perry
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  The presence of Mycoplasma hominis in isolates of Trichomonas vaginalis impacts significantly on DNA fingerprinting results.

Authors:  J C Xiao; L F Xie; L Zhao; S L Fang; Z R Lun
Journal:  Parasitol Res       Date:  2007-12-06       Impact factor: 2.289

9.  Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates.

Authors:  Ehab A Abu-Basha; Nasir M Idkaidek; Tareq M Hantash
Journal:  J Vet Sci       Date:  2006-12       Impact factor: 1.672

10.  Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy.

Authors:  Ayman M Noreddin; Walid F Elkhatib; Kenji M Cunnion; George G Zhanel
Journal:  Drug Healthc Patient Saf       Date:  2011-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.